Addex Therapeutics Ltd
SIX:ADXN
Addex Therapeutics Ltd
SIX:ADXN
Price:
0.071 CHF
-3.79%
Updated:
May 15, 2024
Addex Therapeutics Ltd
Research & Development
|
Addex Therapeutics Ltd
Research & Development Peer Comparison
Comparables:
ADCT
ACIU
CRSP
BSLN
IDIA
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Addex Therapeutics Ltd
SIX:ADXN
|
Research & Development
-CHf6.9m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Research & Development
-$127.1m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Research & Development
-CHf54.6m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Research & Development
-$363.6m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Research & Development
-CHf77.9m
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-4%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Research & Development
-CHf368.3m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
See Also
What is Addex Therapeutics Ltd's Research & Development?
Research & Development
-6.9m
CHF
-6.9m
CHF
Based on the financial report for Dec 31, 2023, Addex Therapeutics Ltd's Research & Development amounts to -6.9m CHF.
What is Addex Therapeutics Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-7%
-7%
Over the last year, the Research & Development growth was 53%. The average annual Research & Development growth rates for Addex Therapeutics Ltd have been 13% over the past three years , -7% over the past five years .
You don't have any saved screeners yet
